# Nventric, Inc.

> Nventric, Inc. is a medical device company and contract development and manufacturing organization (CDMO) headquartered in Arcadia, California, with operations in Seoul, South Korea. Founded in 2019 by engineers with backgrounds at Abbott Vascular and Johnson & Johnson, Nventric designs and builds minimally invasive vascular devices - covering neurovascular, coronary, and electrophysiology applications - from concept through scalable, ISO 13485-certified manufacturing. Its own-branded neurovascular line, including the ULTRIVA stent retriever and EVOGLIDE distal access catheter, targets acute ischemic stroke, while its OEM/CDMO services help device companies move products from prototype to commercialization.

- **Founded:** 2019
- **Headquarters:** Arcadia, California, United States
- **Founders:** Sungwoo Min (CEO / Co-Founder (former Abbott Vascular and Johnson & Johnson R&D)), Don Ngo (Co-Founder, Sr. Director of Engineering and Operations)
- **Team size:** Approximately 32 employees (US); LinkedIn lists a 51-200 band combining US and Korea operations
- **Products:** Neurovascular devices, Coronary devices, Electrophysiology devices, Accessory devices, CDMO / OEM services
- **Notable:** ISO 13485 certified medical device quality management system, MFDS (Korea) approval of the EVOGLIDE distal access catheter (January 2026), MFDS (Korea) approval of the ULTRIVA stent retriever, built on Arch-1 technology (June 2026)

## Products & services

- **Neurovascular devices** — ULTRIVA stent retriever / thrombectomy system for acute ischemic stroke, EVOGLIDE distal access catheters, aspiration catheters, balloon guiding catheters, and revascularization devices.
- **Coronary devices** — Drug-eluting stents, balloon catheters, guide extension catheters, and scoring balloon catheters.
- **Electrophysiology devices** — Pulse field ablation catheters, ablation catheters, and diagnostic / high-density mapping catheters.
- **Accessory devices** — Hemostasis valves (Superior DHV, Flex DHV, Flex RHV rotating hemostasis valve) and PICC lines.
- **CDMO / OEM services** — End-to-end medical device development: R&D and engineering, design optimization, collaborative prototyping, verification/validation and testing, regulatory strategy and global compliance, clinical trial support, and scalable ISO 13485-certified manufacturing.
- **Arch-1 platform** — A proprietary single-tube processing platform for ultra-micro tubing that maximizes structural integrity, with radiopaque markers integrated directly into stent struts for X-ray visibility.

## Achievements

- ISO 13485 certified medical device quality management system
- MFDS (Korea) approval of the EVOGLIDE distal access catheter (January 2026)
- MFDS (Korea) approval of the ULTRIVA stent retriever, built on Arch-1 technology (June 2026)
- Reported revenue CAGR of approximately 52.9% over four years
- Closed a pre-IPO round of KRW 34.5 billion (~US$22.6M) in June 2026 ahead of a planned KOSDAQ listing

## Latest updates

- **2026-01** — EVOGLIDE distal access catheter receives MFDS (Korea) approval.
- **2026-06** — ULTRIVA stent retriever receives MFDS approval, completing Nventric's acute ischemic stroke device lineup.
- **2026-06** — Closed a KRW 34.5 billion (~US$22.6M) pre-IPO round and appointed Kiwoom Securities as lead underwriter, accelerating preparations for a KOSDAQ listing.

## Links

- Website: https://nventric.com
- LinkedIn: https://www.linkedin.com/company/nventric

---

Profile page: https://yespress.io/nventric-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-13